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Edited by Robert B. RussellAbstract Revealing mechanisms underlying complex diseases
poses great challenges to biologists. The traditional linkage
and linkage disequilibrium analysis that have been successful in
the identiﬁcation of genes responsible for Mendelian traits, how-
ever, have not led to similar success in discovering genes inﬂuenc-
ing the development of complex diseases. Emerging functional
genomic and proteomic (omic) resources and technologies pro-
vide great opportunities to develop new methods for systematic
identiﬁcation of genes underlying complex diseases. In this re-
port, we propose a systems biology approach, which integrates
omic data, to ﬁnd genes responsible for complex diseases. This
approach consists of ﬁve steps: (1) generate a set of candidate
genes using gene–gene interaction data sets; (2) reconstruct a ge-
netic network with the set of candidate genes from gene expres-
sion data; (3) identify diﬀerentially regulated genes between
normal and abnormal samples in the network; (4) validate regu-
latory relationship between the genes in the network by perturb-
ing the network using RNAi and monitoring the response using
RT-PCR; and (5) genotype the diﬀerentially regulated genes
and test their association with the diseases by direct association
studies. To prove the concept in principle, the proposed approach
is applied to genetic studies of the autoimmune disease sclero-
derma or systemic sclerosis.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Regulation1. Introduction
The traditional paradigm for genetic studies of diseases is to
connect DNA variation with phenotypic variation [1]. The ma-
jor tools for identiﬁcation of genes inﬂuencing traits are link-
age analysis and association studies [2]. Although linkage
analysis and association studies are successful in localizing
genes responsible for Mendelian diseases, their applications
to identiﬁcation of genes causing complex diseases have not
led to similar success [3]. The discovery of causative genes
for complex diseases poses great challenges to biologists
because disease develops as a consequence of interactions
between multiple DNA variants and exposures to environmen-*Corresponding author.
E-mail address: Xiaodong.Zhou@uth.tmc.edu (X. Zhou).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2005.08.058tal agents varying over time and space, which are organized
into networks [4].
Emerging genomic, transcriptomic, proteomic, and meta-
bolomic (omic) resources and technologies are revolutionizing
biomedical research and allow a transition from the traditional
paradigm for genetic studies of complex diseases to a new par-
adigm based on systems biology. The systems biology ap-
proach to genetic studies of complex diseases has several
remarkable features. First, the systems biology approach as-
sumes that the majority of genes function through complex
networks. Biological networks abstractly represent biological
systems and capture their systemic properties [5]. In the sys-
tems biology approach, complex traits will not only be dis-
sected by individually studying some components of the
networks, but also will be investigated by studying networks
as a whole. Second, the data from any single approach may
contain incomplete information due to the occurrence of false
negatives and false positives [6]. The data from distinct omic
sources may be complementary to each other. Therefore, the
systems biology approach integrating DNA variation, gene
expression, protein–protein interaction and phenotypic varia-
tion will increase the reliability of discovering causative genes
for complex diseases.
One of the key issues in developing a systems biology ap-
proach to genetic studies of complex diseases is how to eﬃ-
ciently integrate various omic data sets and to maximally
extract disease-relevant information. To address this issue,
we propose the following schemes for applying a systems biol-
ogy approach to unraveling the genetic mechanisms of com-
plex diseases.
First, we can select and model candidate genetic networks.
Widely used genomic and transcriptomic methods for complex
disease studies have focused on candidate gene approaches.
Most genetic association studies have been conducted as can-
didate polymorphism or gene studies [7]. A commonly used
method for using gene expression in dissecting the molecular
basis of the disease is to identify diﬀerentially expressed genes
[8]. However, the status of the cell and cellular processes is lar-
gely determined by a number of genes interwoven into net-
works, rather than a few genes [9]. An alternative method to
a candidate gene approach is a candidate genetic network
strategy. Candidate genetic network approaches will be useful
not only for identifying disease genes, but also for elucidating
pathogenesis and discovering treatments for diseases. Selection
of candidate genetic networks can be accomplished by (1)
choosing a set of candidate genes from either linkage analysis
or gene–gene interaction data sets, or gene expression analyses,ation of European Biochemical Societies.
5326 M. Xiong et al. / FEBS Letters 579 (2005) 5325–5332and then reconstructing genetic networks from expression pro-
ﬁles of a selected set of candidate genes or (2) searching liter-
ature and network databases. After the candidate genetic
networks are selected, we then model quantitatively genetic
networks. We propose to use structural equations [10] as a
framework for genetic network modeling.
Second, we can identify diﬀerentially regulated genetic net-
works. Diﬀerential expression of genes is a widely used concept
for identifying genes that are able to discriminate cell pheno-
types. However, the level of gene expression does not reﬂect
genetic changes. Causes of diﬀerential expression are multiple.
Diﬀerential expression of genes between normal and abnormal
tissues may be due either to mutation of its own gene or the
eﬀects of expression changes of other genes in the network.
We often observe that the degree of diﬀerential expression of
one gene due to its own mutations is lower than that of the
downstream genes in the network whose expression levels are
aﬀected by expressions of upstream genes in the network.
Functional mutations in the gene often cause changes in
regulation.
The functional mutation of the gene may have more impact
on its regulation than on its expression. We expect that due to
the accumulation of mutations, the regulation of some genetic
networks in abnormal cells will be signiﬁcantly diﬀerent from
that in normal cells. Uncovering such diﬀerences may help to
identify the cause of the diseases. Coeﬃcient parameters in
the structural equations measure the regulatory eﬀects of one
gene on others or the strength of the gene–gene interaction,
and form a matrix that is referred to as a regulatory matrix.
Identiﬁcation of diﬀerentially regulated genetic networks can
be accomplished by measuring diﬀerences in a norm of the reg-
ulatory matrix between normal and abnormal samples. By
identifying diﬀerentially regulated genetic networks, we are
likely to discover a set of genes and genetic networks that inﬂu-
ence the development of diseases.
Third, we validate the regulatory relationship between genes
in the network by perturbing the network using RNA silencing
(RNAi) or antisense RNA and measuring the response using
RT-PCR. Due to biological and experimental variation, the re-
sults of diﬀerentially regulated genetic networks from gene
expression analysis may not be reliable and need to be con-
ﬁrmed. RNAi coupled with RT-PCR is a powerful tool for
changing gene regulation and can be used to examine the accu-
racy of predictions of regulatory relations between genes in ge-
netic network modeling.
Fourth, we previously assumed that changes in regulatory
eﬀects may come from mutations. To test this hypothesis, we
can genotype the diﬀerentially regulated genes and test for
associations of the mutations with the disease as well as with
regulatory eﬀect changes.
To prove the principle of concept, the proposed scheme for
systems biology approach to complex diseases was applied to
genetic studies of scleroderma or systemic sclerosis (SSc).2. Selection of a set of candidate genes
For ease of presentation, we use our studies of SSc as an
example to describe a scheme of a systems biology approach
to genetic studies of a complex disease. SSc is a multi-system
disease of unknown etiology characterized by cutaneous and
visceral ﬁbrosis, microvascular damage and autoimmune phe-nomena [11]. Although candidate genes are not obvious, there
are still multiple ways to select them. The candidate genes can
be selected by (1) literature review, (2) linkage and association
studies and (3) gene or protein expression data analysis. Here,
we select candidate genes by identifying diﬀerentially expressed
genes from microarray data analysis of skin ﬁbroblasts.
Great biological variability exists within each individual.
Causes of diﬀerential expressions of genes between normal
individuals and patients with a disease can be due to either ge-
netic diﬀerences or diﬀerences in environmental exposures. To
reduce the impact of genetics on the diﬀerential expressions of
the genes, we conducted twin studies that used 16 pairs of af-
fected and unaﬀected SSc twins. Among these twins, 11 pairs
were monozygotic and 5 were dizygotic. Each pair represents
an SSc patient and a normal individual. Fibroblast strains
were cultured from skin biopsies of lesional and non-lesional
skin of aﬀected twins and normal skin of unaﬀected twins
(total 48 samples). Oligo microarrays containing 16650 human
genes were used in gene expression proﬁling of cultured ﬁbro-
blasts of these twins [12].
We postulated that if the expression levels of the genes
between monozygotic SSc patients and their normal twins
showed no signiﬁcant diﬀerences, but expression levels
between dizygotic SSc patients and their normal pairs, or be-
tween monozygotic SSc patients and dizygotic normals showed
signiﬁcant diﬀerences, then the diﬀerence in gene expressions
between SSc patients and normal individuals is more likely
due to genetic diﬀerences. There are four ways to compare
the diﬀerential expressions of the genes between dizygotic
SSc patients and their normal twin pairs or between monozy-
gotic SSc patients and the dizygotic normal twins: (1) compar-
ison between lesional skin of dizygotic SSc patients and that of
their paired normal twins; (2) comparison between non-
lesional skin of dizygotic SSc patients and their paired twins;
(3) comparison between lesional skin of monozygotic SSc pa-
tients and dizygotic normals; and (4) comparison between
non-lesional skin of monozygotic SSc patients and dizygotic
normals. Table 1 lists genes whose P-values showed signiﬁ-
cantly diﬀerential expression equal or less than 0.05 in at least
three of the above comparisons.
Collagens are important components of the extracellular
matrix (ECM) and connective tissue growth factor (CTGF)
is a cysteine-rich secreted protein. Earlier studies have shown
that transforming growth factor (TGF)-b induces CTGF
expression and that TGF-b pathways, including CTGF as a
downstream mediator, can induce collagen production [13].
The TGF-b pathways regulate multiple biological processes,
including inﬂammation, skeletal development, wound repair,
diﬀerentiation and apoptosis [14].
Because of the complexity of TGF-b pathways, the complete
structure of the network has not been elucidated. Table 2 lists
the genes that are directly or indirectly involved in TGF-b
transduction pathways and which show diﬀerential expression
in ﬁve comparisons of our SSc twin studies. Collagen types I,
III and XI, SPARC, MAD3, CTGF and CREB demonstrated
signiﬁcantly diﬀerential expression in at least one comparison
between SSc patients and normal controls, but showed no sig-
niﬁcant diﬀerential expressions between lesional skin of mono-
zygotic patients and their paired normal twins. This implies
that diﬀerential expression of these genes may be due to genetic
diﬀerences in one or more of them. Below we will study how to
use a structural equation model as a simpliﬁed representation
Table 2
P-values of 10 genes in TGF-b pathways showing signiﬁcantly diﬀerential expressions
Gene name Dizygotic lesion/
normal pair
Monozygotic lesion/
dizygotic normal
Dizygotic non-
lesion/dizygotic
normal
Monozygotic
non-lesion/
dizygotic normal
Monozygotic lesion/
normal pair
P-value Fold P-value Fold P-value Fold P-value Fold P-value Fold
COL XIA1 0.0404 4.3987 0.018 8.4834 0.0157 21.899 0.0148 22.3686 0.3667 0.7032
SPARC 0.2002 1.6255 0.0501 1.5577 0.0008 3.9864 0.0097 4.2166 0.4531 0.7764
TGFB1 0.1445 1.4403 0.473 0.8009 0.08 1.6504 0.2289 1.1788 0.2889 0.6138
TGFB2 0.4069 0.8584 0.2541 1.3879 0.3167 0.9645 0.1235 0.8419 0.0130 1.9115
MAD3 0.3762 0.897 0.4454 1.1587 0.032 0.5716 0.1359 0.7637 0.4955 0.9746
CTGF 0.031 3.7412 0.0619 2.9199 0.0085 6.3289 0.0309 6.0569 0.1908 1.0902
CREB 0.4672 0.9837 0.0244 0.6021 0.1938 0.7474 0.1083 0.7344 0.442 1.1187
Plasminogen 0.1093 1.1769 0.2963 0.9447 0.0739 1.3732 0.0655 1.8568 0.4981 0.8668
COL 1A2 0.0143 0.5627 0.0408 0.7861 0.14 0.8912 0.4224 1.2339 0.4588 0.7034
COL 3A1 0.3083 2.8334 0.3872 0.8992 0.0145 3.8956 0.2015 2.9321 0.1194 0.3658
Table 1
Genes showing signiﬁcantly diﬀerential expression in at least three comparisons
Gene name Monozygotic
lesion/normal pair
Dizygotic lesion/
normal pair
Monozygotic lesion/
dizygotic normal
Dizygotic non-lesion/
normal pair
Monozygotic
non-lesion/
dizygotic normal
P-value Fold P-value Fold P-value Fold P-value Fold P-value Fold
COL XIA1 0.3667 0.7032 0.0404 4.3987 0.018 8.4834 0.0157 21.899 0.0148 22.369
OCRL 0.1698 1.3261 0.0371 3.4459 0.0462 2.4577 0.0076 4.8684 0.0006 5.6031
PNMT 0.106 1.0773 0.0113 3.8834 0.0131 2.53 0.0178 2.0229 0.0609 2.1629
CTGF 0.1908 1.0901 0.0311 3.7412 0.0619 2.9199 0.0085 6.329 0.0309 6.0569
PRKAA2 0.4613 0.8258 0.011 3.4701 0.0837 2.124 0.0321 3.8 0.0271 6.2326
CPR8 0.2456 0.6822 0.0468 3.393 0.1686 1.6322 0.0276 2.531 0.0387 2.2136
*Gene names: COL, collagen; CRL, oculocerebrorenal syndrome of Lowe; PNMT, phenylethanolamine N-methyltransferase; CTGF, connective
tissue growth factor; PRKAA2, protein kinase, AMP-activated, alpha 2 catalytic subunit, CPR8, cell cycle progression 8 protein.
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interactions between these ten genes.3. Reconstruction and modeling of genetic networks
We start with modeling of genetic networks based on some
known networks. A genetic network can be represented by a
path diagram. The path diagram consists of nodes represented
by letters, and edges represented by lines. The nodes of the
path diagram correspond to variables. The directed edges be-
tween nodes denote the direction of the regulatory relationship
between the nodes (variables) connected by the edges and indi-
cate a directed regulatory inﬂuence of one gene on another.
The directed edges can represent either activation (positive
control) or inhibition (negative control).
Variables in path diagrams can be classiﬁed into two basic
types: observed variables that can be measured and the residual
error variables that cannot be measured and represent all other
un-modeled causes of the variables. Most observed variables
(e.g., gene expression levels) are random. Some observed vari-
ables might be non-random or control variables (e.g., drug
doses) whose values remain the same in repeated random sam-
pling or might be manipulated by the experimenter. The
observed variables will be further classiﬁed into exogenous vari-
ables, which lie outside the model, and endogenous variables,
whose values are determined through joint interaction with
other variables within the system. All non-random variables
and some of the gene (or protein) expression data (e.g., initiatorsof pathway) can be viewed as exogenous variables. Most of the
gene (or protein) expression data are viewed as endogenous vari-
ables. The terms exogenous and endogenous are model speciﬁc.
It may be that an exogenous variable in one model is endoge-
nous in another. The observed variables are enclosed in boxes
and the error variables are not enclosed at all.
Linear structural equations can be used to model quantita-
tively genetic networks. Let Y be a vector of the p endogenous
variables and X be a vector of q exogenous variables. Occa-
sionally, one or more of the Xs are non-random. We denote
the errors by e. We assume that E [e] = 0 and that e is uncor-
related with the exogenous variables in X. We also assume that
ei is homoscedastic and non-autocorrelated [10]. Then, gene
expressions in the genetic network are modeled by the follow-
ing linear structural equations:
Y ¼ BY þ CX þ e; ð1Þ
where B is a p · p matrix and C is a p · q matrix. The elements
of the coeﬃcient matrices B and C describe the regulatory (or
causal) eﬀects of one gene on the other, or a non-random var-
iable on the gene, which are a direct regulatory inﬂuence of one
variable on the other. Therefore, throughout the paper, the
matrices B and C are referred to as the regulatory matrices.
Since the genetic networks are not fully connected, many ele-
ments in the matrices B and C will be zero. The matrices B
and C are, in general, sparse. The matrix B can describe feed-
back relations in the path diagram. The structural equations
can model directed cyclic graphs and hence genetic networks
with feedback loops [10].
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R ¼ RðhÞ;
where R is the population covariance matrix and R(h) is the
covariance matrix. The above equation implies that each ele-
ment of the covariance matrix is a function of model param-
eters. To ensure that parameter estimators are consistent and
unbiased, the estimation procedures derive from the relation
of the covariance matrix of the observed variables to the
structural parameters. The unknown parameters are esti-
mated so that the implied covariance matrix R is close to
the sample covariance matrix S. To know when our estimates
are as ‘‘close’’ as possible, we must deﬁne ‘‘close’’, that is, we
require a function that is to be minimized. The most widely
used ﬁtting function is based on the method of maximum
likelihood (ML) deﬁned by maximizing the likelihood func-
tion or its log:
FML ¼ log jRðhÞj þ TrðSR1ðhÞÞ  log jSj  ðp þ qÞ;
where p and q are the number of endogenous and exogenous
variables, and Tr denotes the trace of a matrix. The ﬁtting
function FML compares the diﬀerence between the observed
and predicted covariance matrices. In general, FML is a compli-
cated non-linear function of the structural parameters, and
explicit solutions are not always found. Instead, a Newton
unconstrained optimization procedure is employed to ﬁnd
solutions [11].
A linear structural equation model was applied to analyzing
the expression proﬁles of ten genes in these twin studies. The
tissue samples include lesional and non-lesional skin of 11
monozygotic and 5 dizygotic patients, and unaﬀected skin of
their 16 normal pairs. Since we assume that the structure of
the networks with ten candidate genes are unknown, we
repeatedly applied genetic algorithms to the data set 200 times.
The path diagram of the network with the largest ﬁtting prob-
ability P = 0.8864 is shown in Fig. 1. The structural equations
for the network were given byTGF- 1β
SMAD3
-0.2242
-0.1246
CREB
CTGF C
COL11A1 COL3
-0.6359
-0.4031
-0.17
1.3750
0.5916
0.9124
-0.6
Fig. 1. The scheme of path diagram for TGF-b pathways with 10 genes recon
tissue samples and 32 normal tissue samples. The number along the edges wSMAD ¼ 0:2242TGF b1 0:1242TGF b2;
CTGF ¼ 0:6359SMAD 0:4031CREBþ 1:3750SPARC;
Collagen I ¼ 0:1720CREB 0:2679SPARC;
Collagen III ¼ 0:5916CTGF 0:6155Collagen I;
Collagen XI ¼ 0:9124CTGF;
Plas min ogen ¼ 0:1331SPARC 0:1581TGF b2.
The coeﬃcients in the equations measure the magnitude of
inﬂuence of one gene on the expression of another gene and
hence are referred to as the regulatory eﬀects of the genes.
The positive and negative regulatory eﬀects of the gene indi-
cate activation and inhibition, respectively.
The proposed algorithm correctly identiﬁed the structure of
the network. The regulatory relations between the genes in the
reconstructed network can be conﬁrmed by the experiments.
Numerous studies have shown that TGF-b families initiate
activation and the transduction of MAD3 proteins by binding
to TGF-b receptors type I and type II [15]. Since the regulatory
eﬀects of TGF-b1 and TGF-b2 on MAD3 and the regulatory
eﬀect of MAD3 on CTGF were negative, TGF-b1 and TGF-
b2 inhibit MAD3, which in turn increased expression of
CTGF. This was supported by the report that TGFb increases
expression of CTGF markedly in human ﬁbroblasts [16].
CTGF was reported as a downstream mediator of bioactivities
of TGF-b [17]. CTGF also is reported to enhance expression of
collagen [18]. SPARC is shown to regulate the expression of
collagen type I in mesangal cells [19]. Previous data also con-
ﬁrm that CREB blocks expression of CTGF and collagen type
I [20].4. Diﬀerentially regulated genetic networks
Diﬀerential regulation is a useful concept of genetic net-
works for identifying mutations causing diseases. Before we
investigate how to use diﬀerentially regulated genetic networks-0.1581
βTGF- 2
SPARC
Plasminogen
OL1A1
A1
20 0.1331
-0.2679
155
structed from gene expression data in SSc studies of total 16 abnormal
as the estimated regulatory eﬀect of one gene on another.
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ferential regulation of the gene between normal and abnormal
samples. Let A = [B C] be a coeﬃcient matrix of structural
equations for modeling a genetic network. Let A1 and A2 be
its corresponding coeﬃcient matrices in the normal and abnor-
mal tissue samples. Let W = A1  A2 and wij be an element of
the matrix W. Since wij is a parameter in the network, its
asymptotic standard deviation can be calculated from the
square root of the main diagonal of the asymptotic covariance
matrix of the estimated parameters in the network and denoted
by SW ij . We deﬁne the test statistic TG as follows:
TG ¼ W ijSW ij
.
Although the exact distribution of TG is unknown, its asymp-
totical distribution can be approximated by a t distribution
with N  2 degrees of freedom. This statistic can be used to
test the diﬀerence of the regulatory eﬀect of one gene on an-
other between normal and abnormal tissues.
The diﬀerence of the regulatory eﬀect of one gene on another
cannot measure the diﬀerence in the global behavior of the ge-
netic networks between normal and abnormal tissues. A simple
quantity to measure the diﬀerence in global behavior of genetic
networks between the normal and abnormal tissues is the larg-
est absolute value of the diﬀerence of the regulatory eﬀect of
one gene on another in the network between the normal and
abnormal tissues, i.e., w0 ¼ maxi;j j wij j¼j wi0j0 j. The statistic
TG for testing the diﬀerence of individual regulatory eﬀects
can be used to test the diﬀerence in global behavior of genetic
networks. Speciﬁcally, the statistic for testing the diﬀerential
regulation of the genetic networks is given by
T G0 ¼
wi0j0
Swi0 j0
.
The P-value is calculated by a permutation test. The gene
expression proﬁle matrix is randomly permuted, and the struc-TGF-β1
SMAD3
753)-0.3707 (-0.1
-0.1206
CRE
CTGF C
COL11A1 COL3
0.7857
(-0.5696)-0.7817
(-0.1390)
0.10
(-0.6879)
1.9461
(1.3643)
0.8731
(0.5607)
0.7650 (0.9977)
-1.9
Fig. 2. The scheme of path diagram for TGF-b pathways with 10 genes reco
and 16 abnormal tissue samples. The number along the edges was the estim
samples. The number in parenthesis along the edges was the estimated regultural equation model and genetic algorithms are applied to
randomly permutated gene expression data to reconstruct the
genetic network hundreds or thousands of times. Then, we
calculate T G0 and obtain an empirical distribution of T G0 .
The P-value of the test is then deﬁned as the probability that
T G0 exceeds its observed value. The statistic T G0 can be used
to measure the diﬀerence in regulation of the genetic network.
Identiﬁcation of diﬀerentially regulated genetic networks
consists of three steps. First, we reconstruct genetic networks
using structural equations and gene expression data in all
available samples. Second, we ﬁx the structure of the genetic
networks and then estimate network parameters by using gene
expression data of normal and abnormal samples. Third, we
rank the genetic networks according to some statistics, which
measure the extent of the diﬀerence in regulatory eﬀects of
the genetic networks between normal and abnormal tissue
samples.
In twin studies, for the reconstructed genetic network shown
in Fig. 1, we estimated regulatory eﬀects of the genes in the net-
work by using gene expression data of abnormal samples con-
sisting of lesional skin of 11 monozygotic SSc patients and 5
dizygotic SSc patients and putative normal samples consisting
of non-lesional skin of 11 monozygotic and 5 dizygotic SSc
patients and skin of 11 normal monozygotic and 5 dizygotic
pairs, respectively. The results are shown in Fig. 2. The number
in parenthesis along the edges was the regulatory eﬀect of the
genes in the normal tissue samples. The largest diﬀerence of the
regulatory eﬀects of the genes was 1.3553 (T G0 ¼ 12:4387,
P-value = 1.1102 · 1016), which was associated with the regu-
lation of CREB on CTGF, where the P-value was obtained by
a permutation test. In the normal tissues, the function of
CREB is to inhibit the expression of Collagen type I and
CTGF, which in turn regulates the expression of collagen
III. As Fig. 2 shows, in the abnormal tissues, CREB increased
the expression of collagen type I and CTGF, which in turn in-
creased the expression of collagen type III. From Fig. 2, weTGF-β2
B SPARC
Plasminogen
OL1A2
A1
-0.05687
(-0.2013)
31 (-0.1211) 0.1299 (0.1352)
0.2837
(-0.4738)
573 (-0.4372)
nstructed from gene expression data of total 32 normal tissue samples
ated regulatory eﬀect of one gene on another from abnormal tissue
atory eﬀect of one gene on another from normal tissue samples.
Fig. 3. Comparison of transcript levels of SPARC, COL1A2 and
COL3A1 in diﬀerent conditions. (A) Cultured ﬁbroblasts with
transfection media. (B) Cultured ﬁbroblasts with SPARC siRNA
transfection 10 lg/ml for 72 h. (C) Cultured ﬁbroblasts treated with
TGF-b1 10 ng/ml. (D) Cultured ﬁbroblasts with SPARC siRNA
transfection 10 lg/ml for 24 h before addition of TGF-b1 10 ng/ml.
Error bars represent standard deviation in four assays.
5330 M. Xiong et al. / FEBS Letters 579 (2005) 5325–5332can also see that SPARC changed regulatory roles from nega-
tive control to positive control when the normal skin tissues
became lesional. In the normal tissues, SPARC inhibited
expression of collagen type I, but increased production of col-
lagen type I.
The above observations can be well supported by previous
experiments and explained by the pathogenesis of SSc. SSc is
a chronic multi-system disease. It is believed that widespread
tissue ﬁbrosis is due to expansion of ﬁbrogenic clones of tissue
ﬁbroblasts, which produce excessive amounts of ECM compo-
nents, such as collagens and ﬁbronectin [11]. Growth factors
and matricellular proteins are believed to play major roles in
the maintenance of the homeostasis of the ECM. In SSc
tissues, increased activities of growth factors or cytokines, such
as TGF-b and CTGF, are well documented [21]. TGF b signal-
ing in SSc tissue is believed to play important role in ﬁbrotic
process [21]. The CTGF is a downstream gene in TGF-b
signaling [17]. Transfection of the CTGF gene into normal
ﬁbroblasts induced an autocrine ﬁbrotic phenotype including
over-production of collagens [22]. SPARC is a matricellular
protein and an important regulator of cell–matrix interaction.
Our previous studies have demonstrated an over-expression of
SPARC gene in SSc ﬁbroblasts and an increased level of
SPARC protein in both cellular lysates and culture media in
SSc [23]. It is also reported that SPARC-null cells showed
decreased expression of collagen type I and addition of recom-
binant SPARC to SPARC null cells restored the expression of
collagen type I to 70% [19].5. Validation by perturbing networks and genetic association
studies
The inferred regulatory relations between the genes in the
network should be validated by perturbing network and ana-
lyzing its response to perturbation. The changes of regulatory
roles of the genes from activation to inhibition or vice versa
from inhibition to activation due to aﬀection of tissues also
should be validated by perturbing network. Several methods,
for example, antisense RNA and RNA interference, can be
used to perturb networks.
We used SPARC siRNA and CTGF siRNA to suppress
the expression of SPARC and CTGF and RT-PCR to mea-
sure changes of expressions of collagen type I and type III
for investigations of regulatory relations between genes in
the network. Fig. 3 shows eﬀects of SPARC siRNA and
CTGF siRNA and TGF-b1 in transfected and normal ﬁbro-
blasts. Several features emerged from Fig. 3. First, it showed
in normal ﬁbroblasts that TGF-b1 increased expression of
CTGF and collagen type III. This observation was consistent
with prediction of the structural equation model for the net-
work. In both lesional and non-lesional skin tissues, regula-
tion of TGF-b1 on CTGF through negative control of
TGF-b1 on MAD3 and MAD3 on CTGF. Therefore, the
structural equation model predicted that addition of TGF-
b1 would increase expression of CTGF, which in turn in-
creased the expression of collagen type III.
In ﬁbroblasts transfected with SPARC siRNA, we observed
that expression of both collagen type I and type III were de-
creased. The structural equation model precisely predicted a
large reduction of expression of collagen type I and type III
by inhibition of the SPARC gene. Signiﬁcant changes in regu-lation of a gene may imply the occurrence of a mutation or
gene variations within the gene, which provides information
for identifying disease genes. This was supported by associa-
tion studies of SPARC with SSc. Our previous genetic associ-
ation studies in an isolated population with a high prevalence
of SSc (Choctaw Indians), as well as in a multi-ethnic cohort of
SSc patients, strongly suggest that the SPARC gene inﬂuenced
disease susceptibility [23].6. Discussion
We present gene microarray studies of disease-discordant
SSc twins as an example to illustrate the power of a systems
biology approach to genetic studies of complex diseases. The
traditional paradigm for identifying disease susceptibility
genes is positional cloning that connects DNA variation to
phenotypic variation. However, there is an intermediate omic
world between the DNA genotypes and the disease phenotypes
– end point observations. The system from occurrence of DNA
mutations to phenotypes through molecular events at the gene
and protein level is highly likely to be organized into compli-
cated biological networks. The number of paths from DNA
genotypes to the end point observations – phenotypes are
numerous. This may explain why positional cloning can only
lead to limited success in identiﬁcation of causative disease
genes. It is therefore necessary to relate DNA variation to phe-
notypic variation through an omic world organized into bio-
logical networks.
Systems biology that integrates genetic, transcriptomic, pro-
teomic and metabolomic data to understand a whole biological
system provides an exciting new paradigm for genetic studies
of diseases. DNA genotypes provide only partial information
on the connection of DNA to phenotypic variation. It is unli-
kely to directly map DNA genotypes to their corresponding
phenotypes using DNA data alone. In the past decade, great
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vast amounts of valuable data, including genotyping, proﬁling
of mRNA, protein expression, gene–gene interaction, protein–
protein interaction and biological networks. The omic data
provide the basis to conduct systems biology analyses for ge-
netic studies of complex diseases. The analyses integrating
omic data oﬀer insight into the pathogenesis of complex dis-
eases that could not be gained by using each type of omic data
independently.
Key elements of a systems biology approach include (1) start
working points, (2) network analysis, and (3) integration. Sys-
tems biology approaches can begin with any one type of omic
data: genotypes, gene expression, protein expression, and met-
abolic proﬁles, and then correlate each type of omic data with
end point observations, phenotypes. Positional cloning begins
with genotype data and attempt to establish linkage or associ-
ation of genotypes with phenotypes. In SSc studies, we started
with gene expression data and intended to associate diﬀeren-
tially expressed genes with SSc. By analyzing gene expression
data in studies of discordant SSc twin pairs, we found that col-
lagens, which are components of the extracellular matrix, and
CTGF, which induces persistent ﬁbrotic tissue formation, are
associated with SSc. The results in the initial stage of gene dis-
covery in the studies of complex diseases are used to identify a
set of candidate genes.
To further analyze data for expanding the list of candidate
genes and establishing formal burden of proof, we suggest
performing network analysis. A gene does not work alone,
but rather functions together with other genes interwoven
into the network. The network analysis has two advantages.
First, it will open a new way to identify causative genes for
diseases. Second, it can provide insights into the pathogenesis
of the disease. In a positional cloning approach, network
analysis is diﬃcult to perform. Although we can incorporate
gene–gene interaction into the disease model, DNA data
themselves do not provide information on reconstruction of
gene networks. We have a long history of studies of genetic
and metabolic networks that have been reconstructed mostly
by experiments. Genetic and metabolic network databases
provide information on the structure of the networks. An
advancement of high throughput omic technologies, inter-
ests in reconstruction of genetic and metabolic networks
using mathematical models coupled with experiments are
now resurging. In our example, we show how to use struc-
tural equations for modeling genetic networks. Starting with
an initial set of candidate genes coupled with model selec-
tion, we reconstructed networks by searching whole genome
gene expression proﬁles. Although the genes in the TGFb
pathway are known, the proposed structural equations for
construction of genetic networks can infer relations between
new, novel and uncharacterized genes. The reconstruction of
genetic networks will expand the initial set of candidate
genes. Alternative to structural equations for modeling genet-
ic networks, Bayesian networks and other statistical methods
can be used to model genetic networks. Advantage of the
structural equations for construction of genetic networks,
compared to Bayesian networks is that structural equations
can model feedback structure of gene regulation networks,
but in general, Bayesian networks are diﬃcult to deal with
feedback regulation. To identify causative genes for disease,
we proposed the concept of diﬀerentially regulated genetic
networks. We postulated that the changes in gene regula-tion in abnormal cells are due to gene variation. The preli-
minary results in SPARC genotyping analysis support this
assumption.
Directionality of interactions was inferred from model
selection, assuming that the network with correct causal rela-
tions should best ﬁt the data. The inferred causality or regu-
latory relations among genes in the network should be
validated by perturbing network using gene and/or protein
regulatory methods. We propose to perturb networks for
examining regulatory relationships between the genes in the
network shown in the network model. This step is necessary
because of biological and experimental variability in gene and
protein expression data. We used RNA interference to per-
turb the networks and RT-PCR to measure gene expression
levels. Total regulatory relations which we inferred are 12. Se-
ven of them were known in the literature and remaining ﬁve
relations were new. The results show that the identiﬁed new
regulatory relationships between SPARC and collagen type
I, SPARC and CTGF, and collagen type I and collagen type
III in the model were supported by perturbation analysis of
the network.
Integration of multiple types of data is important in system
biology studies. Each type of omic data provides only partial
information. More importantly, each omic data is only one
level of multiple level organization of the biological system.
We should study not only the relationships between the genes
within one type of omic data, but also their connections
between diﬀerent types of omic data. For example, we ﬁrst
studied the regulatory relationship between SPARC and colla-
gen type I using gene expression data. Then, we correlated reg-
ulation of SPARC on collagen type I to phenotypes by
estimating the regulatory eﬀect of SPARC on collagen type I
in the structural equation model using gene expression proﬁles
in normal and abnormal tissues separately. We found that reg-
ulation of SPARC on Collagen type I was changed from inhi-
bition in normal tissues to activation in SSc disease tissues. We
further correlated regulation data with DNA genotypes and
found that the regulation changes were likely due to gene se-
quence variation in the SPARC gene. Integration of omic
data allows one to reveal the path from DNA mutation to phe-
notypes through gene–protein-metabolic interaction, and to
gain deeper insights into the developments of the diseases.
The results of TGF-b pathways in SSc are very limited. Like
any statistical inferences, the reliability and robustness of the
model inference depend on the number of tissue samples used
for gene expression proﬁling, which in turn depends on the
number of genes in the networks. There are no theoretic sam-
ple sizes in construction of genetic networks. Heuristically, we
suggested using as many samples as four times of the number
of the genes in the networks. The sample sizes will limit the size
of the inferred genetic networks. One way to overcome this
problem is to decompose a large network into several modules
of the networks with small size. For each module of the net-
work we can make robust inference.
The purpose of this example is to illustrate the basic scheme
of systems biology approach to genetic studies of complex dis-
eases. We did not study the interactions between environments
and genes (in each omic). Environments will deﬁnitely aﬀect
transcription, translation, and metabolism of the genes. We
should keep in mind that the real biological systems are extre-
mely complicated. However, the information available for
biological systems will be increased when we have more omic
5332 M. Xiong et al. / FEBS Letters 579 (2005) 5325–5332data. The increased information in conjunction with develop-
ment of mathematical models will oﬀer exciting perspectives
for uncovering the causes of many diseases.
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